CMA Calls Trump Administration to Promote Restorative Reproductive Medicine Instead of IVF

Philadelphia, Pa. – February 21, 2025 – The Catholic Medical Association (CMA), the largest association of Catholic medical professionals, is calling on the Trump Administration to reconsider its promotion of IVF in favor of a medically sound and morally ethical alternative to couple infertility known as Restorative Reproductive Medicine (RRM). RRM also has a much better track record of success than IVF. 

CMA released the following statement through Dr. Tim Millea, Chairman of the Health Care Policy Committe:

President Trump’s Executive Order to support and promote IVF raises significant concerns, both medically and ethically. The use of these methods brings about many new human lives, yet the vast majority of those lives will be frozen or discarded. If one correctly recognizes that life begins at conception, and that every human life deserves respect and the right to live, then interventions such as IVF are unacceptable. 

Every life is precious and unique, including those conceived via IVF and allowed to live and develop. Sadly, those lives are very few in comparison to those lost in the clinics.

The Catholic Medical Association calls on the Trump Administration to promote more ethical and effective measures to address infertility. In contrast to IVF, Restorative Reproductive Medicine (RRM), provides a thorough evaluation of the cause of infertility and treatment to address it. RRM methods, including NaPro Technology, FEMM and NeoFertility, consistently lead to a higher rate of successful pregnancies with reduced risks and financial costs compared to IVF. With a humane and effective option such as RRM, the White House can demonstrate its resolve to promote respect for life to all Americans.

Search

Check Out The Pulse of Catholic Medicine

  • Catholic Medical Groups Urge FDA to Reinstate Safeguards on Abortion Pill Mifepristone
    Catholic Medical Groups Urge FDA to Reinstate Safeguards on Abortion Pill Mifepristone

    The Catholic Medical Association (CMA), alongside several prominent Catholic health and ethics organizations, has formally requested that the U.S. Food and Drug Administration (FDA) conduct a comprehensive review of the abortion drug mifepristone, citing rising safety concerns—especially in cases involving telemedicine. In a joint letter addressed to FDA Commissioner Dr. Marty Makary, the coalition urges…

Categories